OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
STIM$1.3058

Neuronetics Inc

Advanced Medical Equipment & TechnologyVerified

Neuronetics operates with a high debt-to-equity ratio of 3.08, indicating a capital structure heavily reliant on debt financing. The company holds $42.64 million in cash and equivalents, but this is offset by $59.76 million in long-term debt, resulting in a net cash position of -$17.12 million. The current ratio of 2.58 suggests adequate short-term liquidity, but the negative operating cash flow of -$16.98 million and free cash flow of -$9.85 million highlight ongoing cash burn. Profitability metrics are weak, with a net loss of $9.83 million and an operating loss of $8.51 million. Return on equity is -50.72%, and return on assets is -10.16%, both significantly below industry norms for medical equipment firms. Gross profit of $12.18 million represents 74% of revenue, but this is insufficient to cover operating expenses. The company derives revenue primarily from the sale and rental of its NeuroStar TMS Therapy system, with geographic exposure concentrated in the United States. No material international revenue is disclosed, and the business is highly dependent on a single product line. Outlook for the current fiscal year shows a continuation of losses, with no material revenue growth expected. The company has not provided forward-looking guidance, and historical revenue trends show little to no growth. Analysts have assigned a mean price target of $4.33, but the absence of strong-buy ratings reflects skepticism about near-term value realization. Risk factors include high leverage, negative cash flows, and dependence on a single product. The risk assessment flags a medium liquidity risk and low dilution risk, though the negative net cash position raises concerns about financial flexibility. No recent equity issuance or dilutive events are reported. Recent filings and transcripts show no material changes in business strategy or product pipeline. The company remains focused on expanding NeuroStar adoption through clinical studies and physician education. No new product launches or regulatory approvals were disclosed in the latest reports.

30-day price · STIM-0.48 (-27.3%)
Low$1.25High$2.48Close$1.28As of17 May, 00:00 UTC
Profile
CompanyNeuronetics Inc
TickerSTIM.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Neuronetics Inc develops and commercializes non-invasive medical devices for the treatment of neurological and psychiatric disorders, primarily through its NeuroStar TMS Therapy system.

Classification. Neuronetics is classified in the Advanced Medical Equipment & Technology industry within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Neuronetics operates with a high debt-to-equity ratio of 3.08, indicating a capital structure heavily reliant on debt financing. The company holds $42.64 million in cash and equivalents, but this is offset by $59.76 million in long-term debt, resulting in a net cash position of -$17.12 million. The current ratio of 2.58 suggests adequate short-term liquidity, but the negative operating cash flow of -$16.98 million and free cash flow of -$9.85 million highlight ongoing cash burn. Profitability metrics are weak, with a net loss of $9.83 million and an operating loss of $8.51 million. Return on equity is -50.72%, and return on assets is -10.16%, both significantly below industry norms for medical equipment firms. Gross profit of $12.18 million represents 74% of revenue, but this is insufficient to cover operating expenses. The company derives revenue primarily from the sale and rental of its NeuroStar TMS Therapy system, with geographic exposure concentrated in the United States. No material international revenue is disclosed, and the business is highly dependent on a single product line. Outlook for the current fiscal year shows a continuation of losses, with no material revenue growth expected. The company has not provided forward-looking guidance, and historical revenue trends show little to no growth. Analysts have assigned a mean price target of $4.33, but the absence of strong-buy ratings reflects skepticism about near-term value realization. Risk factors include high leverage, negative cash flows, and dependence on a single product. The risk assessment flags a medium liquidity risk and low dilution risk, though the negative net cash position raises concerns about financial flexibility. No recent equity issuance or dilutive events are reported. Recent filings and transcripts show no material changes in business strategy or product pipeline. The company remains focused on expanding NeuroStar adoption through clinical studies and physician education. No new product launches or regulatory approvals were disclosed in the latest reports.
Key takeaways
  • Neuronetics is capital-intensive with a debt-to-equity ratio of 3.08 and negative net cash.
  • The company is unprofitable, with a net loss of $9.83 million and ROE of -50.72%.
  • Revenue is concentrated in a single product and domestic market, limiting diversification.
  • Analysts assign a mean price target of $4.33, but no strong-buy ratings are issued.
  • Liquidity risk is medium, and dilution risk is low, though cash burn remains a concern.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$16.4M
Gross profit$12.2M
Operating income-$8.5M
Net income-$9.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$17.0M
CapEx-$991.0k
Free cash flow-$9.8M
Total assets$96.8M
Total liabilities$77.4M
Total equity$19.4M
Cash & equivalents$42.6M
Long-term debt$59.8M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$55.3M-$27.6M-$31.2M-$32.5M
FY-3$65.2M-$35.1M-$37.2M-$38.8M
FY-2$71.3M-$30.6M-$30.2M-$30.6M
FY-1$74.9M-$39.0M-$43.7M-$43.0M
FY0$149.2M-$31.4M-$39.0M-$36.4M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$141.2M$85.2M$94.1M
FY-3$116.9M$57.1M$70.3M
FY-2$115.8M$34.2M$59.7M
FY-1$140.9M$27.7M$18.5M
FY0$141.6M$22.4M$28.1M
PeriodOCFCapExFCFSBC
FY-4-$28.0M-$2.4M-$32.5M
FY-3-$30.7M-$3.3M-$38.8M
FY-2-$32.0M-$2.4M-$30.6M
FY-1-$31.0M-$1.5M-$43.0M
FY0-$20.4M-$801.0k-$36.4M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$16.4M-$8.5M-$9.8M-$9.8M
FQ-6$18.5M-$12.2M-$13.3M-$13.2M
FQ-5$22.5M-$11.5M-$12.7M-$12.2M
FQ-4$32.0M-$11.0M-$12.7M-$12.0M
FQ-3$38.1M-$8.1M-$10.1M-$9.2M
FQ-2$37.3M-$7.3M-$9.0M-$8.6M
FQ-1$41.8M-$5.0M-$7.2M-$6.6M
FQ0$34.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$96.8M$19.4M$42.6M
FQ-6$74.1M$9.4M$20.9M
FQ-5$140.9M$27.7M$18.5M
FQ-4$142.0M$35.5M$20.2M
FQ-3$134.7M$27.1M$11.0M
FQ-2$145.5M$27.4M$28.0M
FQ-1$141.6M$22.4M$28.1M
FQ0
PeriodOCFCapExFCFSBC
FQ-7-$17.0M-$991.0k-$9.8M
FQ-6-$22.4M-$1.4M-$13.2M
FQ-5-$31.0M-$1.5M-$12.2M
FQ-4-$17.0M-$219.0k-$12.0M
FQ-3-$20.5M-$471.0k-$9.2M
FQ-2-$21.3M-$585.0k-$8.6M
FQ-1-$20.4M-$801.0k-$6.6M
FQ0-$9.4M-$197.0k
Valuation
Market price$1.30
Market cap$90.5M
Enterprise value$107.6M
P/E
Reported non-GAAP P/E
EV/Revenue6.5
EV/Op income
EV/OCF
P/B4.7
P/Tangible book4.7
Tangible book$19.4M
Net cash-$17.1M
Current ratio2.6
Debt/Equity3.1
ROA-10.2%
ROE-50.7%
Cash conversion1.7%
CapEx/Revenue-6.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 109 companies
MetricSTIMActivity
Op margin-51.7%-19.9% medp25 -150.5% · p75 8.7%below median
Net margin-59.8%-18.4% medp25 -146.8% · p75 8.0%below median
Gross margin74.0%49.9% medp25 36.2% · p75 66.3%top quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-6.0%-3.5% medp25 -7.8% · p75 -1.4%below median
Debt / equity308.0%14.5% medp25 0.9% · p75 54.2%top quartile
Observations
IR observations
Mean price target4.33 USD
Median price target3.00 USD
High price target7.00 USD
Low price target3.00 USD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count3.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.48 USD
Last actual EPS-0.59 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 14:07 UTC#35e8abd2
Market quoteclose USD 1.84 · shares 0.07B diluted
no public URL
2026-05-16 14:07 UTC#37e0dbae
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 14:16 UTCJob: 34e5e086